The antagonist, delivered i.p. as a soluble protein or secreted from virally infected tumor cells, reduced the accumulation of immunosuppressive CD11b+Ly6ClowLy6Ghigh G-MDSCs compared with the untreated and OVV-treated counterparts (Figure 2B; p = 0.03 and p = 0.006, respectively), and also inhibited accumulation of CD4+CD25+Foxp3+ Tregs (Figure 2C; p < 0.05). This evidence concerns the gene FOXP3 and neoplasm.